To the Editor:
Recently, we read a thought-provoking clinical trial entitled “Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomized, double-blind, placebo-controlled trial” . However, the authors did not observe any significant benefit of eplerenone regarding best-corrected visual acuity (BCVA), subretinal fluid (SRF), central subfield thickness, and recurrence in patients with central serous chorioretinopathy (CSCR) compared with placebo. The study also did not explain these observations using possible mechanisms .
In contrast, Petkovsek et al. reported anatomical improvement, including central subfield thickness, macular cube volume, maximum SRF height and diameter achieved within the first year of eplerenone treatment . In another recent study, BCVA was significantly improved and SRF and macular thickness decreased significantly in patients with CSCR treated with oral eplerenone, especially in those under stress . Additionally, it is known that elevated levels of cortisol and endogenous mineralocorticoid dysfunction  in patients with CSCR contribute to choroidal vasodilation, and the inhibition of this pathway may prevent aldosterone-induced choroidal thickening .
To understand these dissimilar results, we should remember that the presence of a focal leakage point on indocyanine green angiography (ICGA) in the absence of choroidal neovascularization (CNV) signals on optical coherence tomography angiography (OCTA) serve as predictive factors for the complete resolution of SRF after oral eplerenone . However, the presence of widespread changes in retinal pigment epithelium (usually in elderly patients) may hinder the favorable outcome of eplerenone treatment. With this in mind, we noticed that the participants’ age included in the VICI study was between 18 and 60 years . Importantly, CSCR in elderly patients is usually complicated with type I CNV with or without aneurysmal changes , especially for refractory and recurrent cases, some of which can be only visualized in OCTA other than dye angiographies . Neovascular CSCR is associated with a worse visual acuity outcome compared to non-neovascular CSCR . We used OCTA to detect CNV secondary to CSCR (Fig. 1). In particular, swept source-OCTA provides a promising CNV detection rate . However, the methodology to exclude CNV is the combination of ICGA and fluorescein angiography in the VICI study , which is failed to detect tiny CNVs in some cases. OCTA was not used in this clinical trial to rule out this type of CNV, which would increase the bias of therapeutic outcomes. In fact, CSCR with CNV might benefit from anti-VEGF treatment .
Current evidence indicates that CSCR can be understood as a subtype of pachychoroid disease characterized by the presence of pachyvessels . Therefore, both retinal and choroidal recovery may be considered desirable treatment outcomes In our previous study, SRF completely resolved 2–3 weeks after photodynamic therapy (PDT), but both mean and subfoveal choroidal thicknesses returned to normal 2–3 months after PDT . Therefore, the premature interruption of treatment may contribute to the relapse of CSCR. For this reason, further studies and a profound reappraisal of published evidence are necessary before changes in current clinical practice are justified.
Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomized, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303.
Petkovsek DS, Cherfan DG, Conti FF, Hom GL, Ehlers JP, Babiuch AS, et al. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Br J Ophthalmol. 2020;104:182–7.
Fraenkel D, Suffo S, Langenbucher A, Seitz B, Din Abdin A. Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2020; 1120672120952648. Online ahead of print.
Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110:698–703.
Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Investig. 2012;122:2672–9.
Van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770.
Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye. 2019;33:14–33.
Min JY, Lv Y, Yu S, Gong YY. Findings of OCT-angiography compared to fluorescein and indocyanine green angiography in central serous chorioretinopathy. Lasers Surg Med. 2018;50:987–93.
Sulzbacher F, Schütze C, Burgmüller M, Vécsei-Marlovits PV, Weingessel B. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Graefes Arch Clin Exp Ophthalmol. 2019;257:1581–90.
Sadda SR. Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy. Eye. 2020;34:1489–90.
Hua R, Liu L, Li C, Chen L. Evaluation of the effects of photodynamic therapy on chronic central serous chorioretinopathy based on the mean choroidal thickness and the lumen area of abnormal choroidal vessels. Photodiagnosis Photodyn Ther. 2014;11:519–25.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Xia, Y., Hua, R. Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy. Eye 35, 3445–3447 (2021). https://doi.org/10.1038/s41433-020-01325-9